Anti-Viral Therapies Market by Type, Application, and Mechanism of Action: Global Opportunity Analysis and Industry Forecast, 2019-2026

Executive Summary

According to the report titled, 'Anti-viral. Therapies Market by Application, Type, and Mechanism of Action: Opportunity Analysis and Industry Forecast, 2019-2026' the global anti-viral therapies market size was valued at $38,316.5 million in 2018, and is projected to reach $46,213.4 million by 2026 registering a CAGR of 2.4% from 2019 to 2026. Antiviral therapies make use of drugs that inhibit the development of the virus causing infection.. These drugs do not kill the target pathogen directly.. These therapies are mostly particular against viral infections and do not cause side effects in the host’s body. Anti-viral therapies are widely used in treating HIV, herpes, hepatitis, influenza and other viral infections such as chicken pox and papilloma.

The factors that drive the growth of the market include rise in prevalence of viral infections globally and presence of robust product pipeline with several pharmaceutical giants. Conversely, higher cost for treating these infections and shift in preference of the patients toward homeopathy and naturopathy are some of the key issues expected to hinder the antiviral therapies market growth. On the contrary, R&D for developing combination therapies to effectively eradicate the infections is anticipated to provide lucrative opportunities for the growth of the anti-viral therapies market during the forecast period.

The global antiviral therapies market is segmented on the basis of application, type, mechanism of action, and region. Based on application, the market is categorized into HIV, hepatitis, herpes, influenza, and other viral diseases. HIV segment was the largest revenue contributor to the anti-viral therapies market in 2018 and is expected to continue this trend during the forecast period, owing to increase in incidences of HIV globally. For instance, as per the data published by UNAIDS, in 2017, around 37 million of the global population is living with HIV. The prevalence of HIV among adults was estimated to be 0.8%. Moreover, an increase in consumption of HIV anti-viral drugs for combating infection is major driving factor for the growth of the anti-viral therapies market for HIV segment. On the basis of type, it is classified into generic drugs and branded drugs. The branded drugs segment is a major revenue contributor to the anti-viral therapies market in 2018 and is expected to continue its dominance throughout the forecast period, owing to availability of large number of branded drugs for treating various viral infections. On the basis of mechanism of action, it is divided into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. The nucleotide polymerase inhibitor segment is considered as the most lucrative segment in the anti-viral therapies market, owing to its increasing usage in Hepatitis C infection and are considered to be the first-line treatment for any viral infection. This increase in the usage of nucleotide polymerase inhibitor for treating viral infection is expected to boost the growth of the market during the forecast period. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the global antiviral therapies market in 2018 and is expected to continue its dominance throughout the forecast period, owing to rise inincidences of infectious diseases across the region. Favorable government initiatives undertaken by the U.S. government to combat the prevalence and occurrence of infectious diseases across the North American region are expected to provide ample opportunities for the growth of the anti-viral therapies market in the coming years. Asia-Pacific is expected to grow at the fastest CAGR during the forecast period due to presence of several generic pharmaceutical players and increase in investment for drug development in South Asian countries.

The report provides a comprehensive analysis of the key players operating in the global anti-viral therapies market, which include F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott Laboratories, AstraZeneca plc, AbbVie Inc., Aurobindo Pharma Limited, Johnson & Johnson, and Merck & Co., Inc. The other players in the value chain (companies not included in the report) include Schering-Plough Corporation, Cipla, and Dr Reddy’s.

Key Findings of the Study:

Nucleotide polymerase inhibitor segment occupied 38.44% share of the global anti-viral therapies market in 2018.
By application, HIV segment is anticipated to grow with the highest CAGR throughout the forecast period.
By type, the generic drugs segment accounted for 46.8% share of the market in 2018.
Asia-Pacific is anticipated to grow at the 2.8% during the analysis period.

Companies Mentioned

• F. Hoffmann-La Roche Ltd.
• Gilead Sciences
• GlaxoSmithKline
• Bristol-Myers-Squibb
• Abbott Laboratories
• AstraZeneca plc
• AbbVie Inc.
• Aurobindo Pharma Limited
• Johnson & Johnson
• Merck & Co. Inc

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.